Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

The 'Fast Money' traders talk Hims & Hers shares falling despite beat as concerns around weight-loss business escalate.

Hims & Hers reported a double beat in Q4, but faced an 18% stock drop after hours. Read why this drop is a good opportunity ...

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

Hims & Hers (HIMS) stock tumbled 20% post-market after the company released its Q4 earnings report and 2025 guidance amid a ...

On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.